Searchable abstracts of presentations at key conferences in endocrinology

ea0026p181 | Neuroendocrinology | ECE2011

GH enhances breast cancer chemoresistance by inhibiting JNK-mediated apoptosis

Minoia M , Gentilin E , Tagliati F , Mole D , Ambrosio M R , Baroni A , degli Uberti E , Zatelli M C

GH and insulin-like growth factor 1 (IGF1) are known to promote breast carcinogenesis. Breast cancer (BC) incidence in not increased in female acromegalic patients, but mortality is greater as compared to general population. We previously demonstrated that GH/IGF1 excess influences BC response to therapy, possibly accounting for the increased mortality. We indeed showed that GH and IGF1 induce cell proliferation of a BC cell line, the MCF7 cells, providing protection towards t...

ea0026p735 | Diabetes (epidemiology, pathophysiology) | ECE2011

Insulin restores salivary secretion in diabetic rats: involvement of Na+/glucose cotransporter SGLT1

Sabino-Silva R , Campello R S , Nakamura H K , Freitas H S , Okamoto M M , Mori R C , Machado U F

Introduction: Considering the high capacity of water transport of Na+/glucose cotransporter SGLT1, the aim of this study was to investigate the potential role the SGLT1 in luminal membrane of ductal cells of salivary glands upon the non-stimulated salivary secretion of diabetic rats. The present study also investigates the presence of glucose transporter GLUT1 in salivary glands of rats.Methods: Non-stimulated salivary secretion and SGLT1/GLUT1 protein (...

ea0025p215 | Nursing practise | SFEBES2011

What is the appropriate time for radioactive iodine re-dosing to achieve cure of persistent hyperthyroidism?

Khalid Yasmeen , Nayak Ullal Ananth , Buch HaritNarendra

Background: Radioactive iodine (RAI) therapy effectively cures hyperthyroidism although a varying proportion of patients need repeat RAI doses. There is no consensus on the timing of redosing for RAI which varies in different centres between 6 weeks and 12 months depending on the perceived time to respond to therapy.Aim: We have undertaken a retrospective study to assess if after the initial RAI dose of 400 MBq a second RAI dose can be administered earli...

ea0025p331 | Thyroid | SFEBES2011

The natural history of endogenous subclinical hyperthyroidism

Vadiveloo Thenmalar , Donnan Peter , Cochrane Lynda , Leese Graham

Objective: To define the rates of progression to frank hyperthyroidism and to normal thyroid function for subclinical hyperthyroid patients (SH).Design: Record-linkage technology was used retrospectively to identify patients with SH in the general population from 1st January 1993 to 31st December 2009.Patients: All residents over 18 years old with at least two measurements of TSH below the reference range for at least 4 months from...

ea0022p535 | Male reproduction | ECE2010

Testosterone partially ameliorates metabolic profile and erectile responsiveness to PDE5 inhibitors in an animal model of male metabolic syndrome

Vignozzi Linda , Filippi Sandra , Morelli Annamaria , Chavalmane Aravinda K , Sarchielli Erica , Vannelli Gabriella B , Mannucci Edoardo , Maggi Mario

Metabolic syndrome (MetS) is a clustering of cardio-metabolic risk factors (hyperglycemia, hypertension, dyslipidemia, visceral fat accumulation) that is also associated with hypogonadism and erectile dysfunction (ED). The study was aimed at clarifying the relationships among MetS, hypogonadism, and ED, we developed an animal model of MetS.Methods: Male rabbits fed a high-fat diet (HFD), with or without testosterone (T) supplementation, were compared wit...

ea0014p473 | (1) | ECE2007

Bloch-sulzberger syndrome, hypothyroidism and a pituitary incidentaloma: a case report

Stojanovic Marko , Miljic Dragana , Doknic Mirjana , Djurovic Marina , Pekic Sandra , Nikolic Milos , Popovic Vera

A female patient, 34 years old, was referred to endocrinologist, for an incidentally discovered interstellar mass on MR, mild subclinical hypothyroidism and hyperprolactinemia, and irregular menstrual cycles. She was diagnosed with Bloch-Sulzberger syndrome (BSS) in neonatal age. Epilepsy, her most prominent component of BSS, was well controlled but only with triple anticonvulsant therapy (Valproate, Carbamazepine, Clonazepam). She was obese, clinically euthyroid, and exhibite...

ea0012oc8 | Young Endocrinologist prize session | SFE2006

Caveolin-1: A regulator of the IGFIR/Akt pathway mediating cellular proliferation but not survival

Matthews LC , Taggart MJ , Westwood M

The insulin-like growth factors (IGFs) signal through the type 1 IGF receptor (IGFIR) to regulate cellular proliferation and survival. A current theory suggests that a subset of plasmalemmal lipid rafts, termed caveolae, may orchestrate such IGF-mediated signalling.In order to investigate the role of caveolae and the marker protein caveolin in controlling IGF signals, two cell models of caveolin deficiency were generated. Using shRNA, caveolin-1 expressi...

ea0057006 | TAOK3 as a regulator of glucose tolerance in obesity | BES2018

TAOK3 as a regulator of glucose tolerance in obesity

Maes B , Fayazpour F , Catrysse L , Lornet G , Lapauw B , Lambrecht BN , Janssens S

Aims or Objectives: We here describe a role for the kinase thousand and one kinase (TAOK) 3 as a modulator of insulin resistance. TAOK3 is one of three members of the TAOK family of kinases, which are classified within the Ste20-like kinases as mitogen activated protein kinase 4 kinases. TAOK3 was identified in a RNAi library screening in C. elegans as a target molecule that could revert an insulin resistance-like state induced by a daf-2 mutation (Devgen, Ghent). Mor...

ea0056p79 | Adrenal medulla | ECE2018

Why is it important to screen secondary endocrine hypertension in resistant cases? Lessons from a patient with progressive renal failure

Esteban Nivelo-Rivadeneira Manuel , Ramos-Gomez Isabel , Dolores Perez-Ramada Maria , Delia Santana-Suarez Ana , Kuzior Agnieszka , Fernandez-Trujillo-Comenge Paula , Acosta-Calero Carmen , Arnas-Leon Claudia , Quintana-Arroyo Sara , Javier Martinez-Martin Francisco

Introduction: Even though most hypertensive patients have essential hypertension, in the resistant cases the prevalence of secondary hypertension is much higher; therefore its screening should be mandatory. Resistant hypertension usually causes a progressive decline of renal function if blood pressure is not adequately controlled. Such decline is often irreversible; however a timely diagnosis leading to a resolutive treatment can alleviate or even revert the progression of the...

ea0056p801 | Pituitary - Clinical | ECE2018

Gonadotroph pituitary macroadenoma inducing ovarian hyperstimulation syndrome

Dyrmishi Blertina , Olldashi Taulant , Puca Entela , Lumi Ema , Ylli Dorina

Case report: We report a young woman with ovarian hyper stimulation syndrome (OHSS), headache, visual field defect and pituitary macro adenoma. The patient was treated about four years ago as pituitary PRL-secreting adenoma with carbergoline. The evaluation of other hormones FSH, LH and Estradiol values wasn’t done. The patient presented to our hospital with abdominal pain and headaches and amenohrrea. The pregnancy test was negative and pelcic ultrasound demonstrated enl...